4:22 PM
 | 
Oct 11, 2018
 |  BC Week In Review  |  Financial News  |  Completed Offerings

Polaris, Arch co-lead series A for MIT spinout Glympse

With $22 million in new series A funding, Glympse Bio Inc. (Cambridge, Mass.) plans to start clinical testing by mid-2019 of its bio-engineered diagnostic for non-alcoholic steatohepatitis (NASH). Glympse is developing injectable bio-engineered activity sensors that emit a signal detectable in urine for diagnostic and drug monitoring purposes.

Polaris Partners and...

Read the full 235 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >